CN113825767A - 包含抗rsv抗体的组合物和剂量方案 - Google Patents

包含抗rsv抗体的组合物和剂量方案 Download PDF

Info

Publication number
CN113825767A
CN113825767A CN202080032470.XA CN202080032470A CN113825767A CN 113825767 A CN113825767 A CN 113825767A CN 202080032470 A CN202080032470 A CN 202080032470A CN 113825767 A CN113825767 A CN 113825767A
Authority
CN
China
Prior art keywords
rsv
patient
antigen
binding fragment
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080032470.XA
Other languages
English (en)
Chinese (zh)
Inventor
A·A·罕
V·皮埃尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Sanofi Pasteur Inc
Original Assignee
MedImmune Ltd
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd, Sanofi Pasteur Inc filed Critical MedImmune Ltd
Publication of CN113825767A publication Critical patent/CN113825767A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
CN202080032470.XA 2019-04-30 2020-04-30 包含抗rsv抗体的组合物和剂量方案 Pending CN113825767A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962840701P 2019-04-30 2019-04-30
US62/840701 2019-04-30
PCT/US2020/030619 WO2020223435A1 (en) 2019-04-30 2020-04-30 Dosage regimens for and compositions including anti-rsv antibodies

Publications (1)

Publication Number Publication Date
CN113825767A true CN113825767A (zh) 2021-12-21

Family

ID=70779897

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080032470.XA Pending CN113825767A (zh) 2019-04-30 2020-04-30 包含抗rsv抗体的组合物和剂量方案

Country Status (15)

Country Link
US (3) US12024553B2 (https=)
EP (1) EP3962940A1 (https=)
JP (2) JP2022531205A (https=)
KR (1) KR20220002427A (https=)
CN (1) CN113825767A (https=)
AU (1) AU2020265676A1 (https=)
BR (1) BR112021020846A2 (https=)
CA (1) CA3138180A1 (https=)
CO (1) CO2021014370A2 (https=)
EA (1) EA202192776A1 (https=)
IL (1) IL287443A (https=)
MX (1) MX2021013248A (https=)
SG (1) SG11202111748TA (https=)
TW (1) TWI861099B (https=)
WO (1) WO2020223435A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
WO2023039584A2 (en) * 2021-09-13 2023-03-16 Medimmune Limited Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018160722A1 (en) * 2017-03-01 2018-09-07 Medimmune Limited Anti-rsv monoclonal antibody formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
LT2950886T (lt) 2013-02-01 2020-07-10 Medimmune, Llc Respiracinio sincitinio viruso f baltymo epitopai
FR3008921B1 (fr) 2013-07-23 2015-12-25 Safran Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece
EP4353316A3 (en) 2014-01-15 2024-08-21 Medimmune Limited Rsv-specific antibodies and functional parts thereof
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018160722A1 (en) * 2017-03-01 2018-09-07 Medimmune Limited Anti-rsv monoclonal antibody formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOSEPH B. DOMACHOWSKE等: "Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants", THE PEDIATRIC INFECTIOUS DISEASE JOURNAL, vol. 37, no. 9, 30 September 2018 (2018-09-30), pages 891, XP055747746, DOI: 10.1097/INF.0000000000001916 *

Also Published As

Publication number Publication date
EA202192776A1 (ru) 2022-01-19
JP2025072444A (ja) 2025-05-09
TWI861099B (zh) 2024-11-11
US20220204593A1 (en) 2022-06-30
JP2022531205A (ja) 2022-07-06
WO2020223435A1 (en) 2020-11-05
TW202106333A (zh) 2021-02-16
CA3138180A1 (en) 2020-11-05
AU2020265676A1 (en) 2021-11-18
SG11202111748TA (en) 2021-11-29
BR112021020846A2 (pt) 2022-01-18
US20240417447A1 (en) 2024-12-19
US20200347120A1 (en) 2020-11-05
CO2021014370A2 (es) 2021-10-29
EP3962940A1 (en) 2022-03-09
KR20220002427A (ko) 2022-01-06
MX2021013248A (es) 2022-01-24
IL287443A (en) 2021-12-01
US12024553B2 (en) 2024-07-02

Similar Documents

Publication Publication Date Title
AU2021202598B2 (en) Compositions and methods for the treatment of immunodeficiency
US20240417447A1 (en) Dosage regimens for and compositions including anti-rsv antibodies
ES2391087T3 (es) Anticuerpos de IL-9 recombinantes y usos de los mismos
US12565526B2 (en) Formulations of anti-RSV antibodies and methods of use thereof
TW202304980A (zh) 經修飾的抗ｔｓｌｐ抗體
US20220380451A1 (en) Biopharmaceutical compositions and methods for pediatric patients
JP2025542128A (ja) メタニューモウイルス融合（ｆ）タンパク質に対する抗体及びその使用
EA046902B1 (ru) Схемы введения доз и композиции, включающие антитела к rsv
RU2807524C2 (ru) Составы антител к rsv и способы их применения
CA3115708C (en) Formulations of anti-rsv antibodies and methods of use thereof
US20250340622A1 (en) Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab
WO2021005232A1 (en) Intranasal administration of neutralising antiviral antibodies
AU2024264265A1 (en) Anti-influenza antibody
WO2022079001A2 (en) Sars-cov-2 antigens, diagnostic and therapeutic uses
HK1091116B (en) Recombinant il-9 antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: United Kingdom

Address after: Cambridge County

Applicant after: MEDIMMUNE Ltd.

Country or region after: U.S.A.

Applicant after: Sanofi Vaccines USA

Address before: Cambridge County

Applicant before: MEDIMMUNE Ltd.

Country or region before: United Kingdom

Applicant before: SANOFI PASTEUR, Inc.

Country or region before: U.S.A.